Increased incidence of acute graft rejection on calcineurin inhibitor-free immunosuppression after heart transplantation

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1862-1867

  Celik, S ^a   Doesch, A O ^a   Konstandin, M H ^a   Kristen, A V ^a   Ammon, K ^a   Sack, F U ^a   Schnabel, P ^a   Katus, H A ^a   Dengler, T J ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Department of Cardiology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BIOPSY; CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NEOPLASM; PRIORITY JOURNAL;

ADULT; AGED; CALCINEURIN; CAUSE OF DEATH; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79959466770     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.12.059     Document Type: Article

References (23)

1. A.O. Ojo, P.J. Held, F.K. Port, and R.A. Wolfe Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 93
2. C. Magee, and M. Pascual The growing problem of chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 994
3. M.R. Mehra Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy Am J Transplant 6 2006 1248
4. J. Odim, J. Wheat, and H. Laks Peri-operative renal function and outcome after orthotopic heart transplantation J Heart Lung Transplant 25 2006 162
5. M. Hojo, T. Morimoto, and M. Maluccio Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 6719 1999 530
6. S.N. Sehgal Sirolimus: its discovery, biological properties, and mechanism of action Transplant Proc 35 3 Suppl 2003 7S
7. H.J. Eisen, E.M. Tuzcu, R. Dorent RAD B253 Study Group Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847
8. H. Valantine, and A. Zuckermann From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation J Heart Lung Transplant 24 4 Suppl 2005 S185
9. J. Groetzner, I. Kaczmarek, and B. Meiser Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure J Heart Lung Transplant 23 2004 770
10. J. Groetzner, I. Kaczmarek, and J. Schirmer Calcineurin inhibitor withdrawal and conversion to mycophenolate mofetil and steroids in cardiac transplant recipients with chronic renal failure: a word of caution Clin Transplant 22 2008 587
11. C.A. Gleissner, A. Doesch, and P. Ehlermann Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy Am J Transplant 6 2006 2750
12. R.W. Johnson, H. Kreis, and R. Oberbauer Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure Transplantation 72 2001 777
13. J. Hunt, H. Bedanova, and R.C. Starling Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation J Heart Lung Transplant 26 Suppl 2 2007 398
14. A. Keogh Calcineurin inhibitors in heart transplantation J Heart Lung Transplant 23 2004 S202
15. M. Schweiger, A. Wasler, and G. Prenner Late acute cardiac allograft rejection: new therapeutic options? Transplant Proc 37 2005 4528
16. H. Eisen, J. Kobashigawa, and R.C. Starling Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors Transplant Proc 37 4 Suppl 2005 4S
17. A. Alam, K. Badovinac, and F. Ivis The outcome of heart transplant recipients following the development of end-stage renal disease: analysis of the Canadian Organ Replacement Register (CORR) Am J Transplant 7 2007 461
18. D.O. Taylor, L.B. Edwards, M.M. Boucek International Society for Heart and Lung Transplantation Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report2006 J Heart Lung Transplant 25 2006 869
19. D.K. Satchithananda, J. Parameshwar, and L. Sharples The incidence of end-stage renal failure in 17 years of heart transplantation: a single center experience J Heart Lung Transplant 21 2002 651
20. S.N. Sehgal, K. Molnar-Kimber, T.D. Ocain, and B.M. Weichman Rapamycin: a novel immunosuppressive macrolide Med Res Rev 14 1994 1
21. C.G. Groth, L. Bckman, and J.M. Morales Sirolimus (rapamycin)based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine Sirolimus European Renal Transplant Study Group Transplantation 67 1999 1036
22. R.S. Poston, M. Billingham, and E.G. Hoyt Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model Circulation 100 1999 67
23. R. Klingenberg, A. Koch, and P.A. Schnabel Allograft rejection of ISHLT grade <3A occurring late after heart transplantationa distinct entity? Heart and Lung Transplant 2003 1005